MA64631A1 - Procédé de production de capside modifié de virus adéno-associé - Google Patents
Procédé de production de capside modifié de virus adéno-associéInfo
- Publication number
- MA64631A1 MA64631A1 MA64631A MA64631A MA64631A1 MA 64631 A1 MA64631 A1 MA 64631A1 MA 64631 A MA64631 A MA 64631A MA 64631 A MA64631 A MA 64631A MA 64631 A1 MA64631 A1 MA 64631A1
- Authority
- MA
- Morocco
- Prior art keywords
- associated virus
- capsid
- modified
- producing modified
- virus capsid
- Prior art date
Links
- 210000000234 capsid Anatomy 0.000 title abstract 5
- 241000702421 Dependoparvovirus Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention se rapporte au domaine de la thérapie génique et de la biologie moléculaire. La présente invention concerne plus particulièrement un procédé de production de capside modifié de virus adéno-associé (aav) et un capside modifié de aav obtenu selon ce procédé, ainsi qu'un acide nucléique séparé codant ledit capside modifié, et un vecteur sur la base d'un virus adéno-associé recombinant pour administrer à un sujet une séquence hétérologue d'acide nucléique comprenant ledit capside modifié.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021124731 | 2021-08-20 | ||
PCT/RU2022/050255 WO2023022631A1 (fr) | 2021-08-20 | 2022-08-18 | Procédé de production de capside modifié de virus adéno-associé |
Publications (1)
Publication Number | Publication Date |
---|---|
MA64631A1 true MA64631A1 (fr) | 2024-05-31 |
Family
ID=85240917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA64631A MA64631A1 (fr) | 2021-08-20 | 2022-08-18 | Procédé de production de capside modifié de virus adéno-associé |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4389880A1 (fr) |
CN (1) | CN118139974A (fr) |
AR (1) | AR126841A1 (fr) |
AU (1) | AU2022328531A1 (fr) |
CA (1) | CA3229580A1 (fr) |
CO (1) | CO2024001768A2 (fr) |
EC (1) | ECSP24013031A (fr) |
IL (1) | IL310949A (fr) |
MA (1) | MA64631A1 (fr) |
TW (1) | TW202317770A (fr) |
WO (1) | WO2023022631A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3431140A1 (de) | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
EP2699270B1 (fr) | 2011-04-22 | 2017-06-21 | The Regents of The University of California | Virions de virus adéno-associé avec capside variant et procédés d'utilisation de ceux-ci |
PL2839014T3 (pl) | 2012-04-18 | 2021-08-23 | The Children's Hospital Of Philadelphia | Kompozycja i sposoby na wysoko wydajny transfer genu za pomocą kapsydu wariantów aav |
ES2871117T3 (es) * | 2016-01-26 | 2021-10-28 | Defensin Therapeutics Aps | Procedimientos para modular la microbiota intestinal |
WO2019222411A1 (fr) * | 2018-05-16 | 2019-11-21 | Spark Therapeutics, Inc. | Cassettes d'expression d'alpha-glucosidase acide optimisées par des codons et leurs méthodes d'utilisation |
-
2022
- 2022-08-18 WO PCT/RU2022/050255 patent/WO2023022631A1/fr active Application Filing
- 2022-08-18 EP EP22858841.4A patent/EP4389880A1/fr active Pending
- 2022-08-18 IL IL310949A patent/IL310949A/en unknown
- 2022-08-18 AU AU2022328531A patent/AU2022328531A1/en active Pending
- 2022-08-18 CN CN202280070178.6A patent/CN118139974A/zh active Pending
- 2022-08-18 MA MA64631A patent/MA64631A1/fr unknown
- 2022-08-18 CA CA3229580A patent/CA3229580A1/fr active Pending
- 2022-08-19 AR ARP220102252A patent/AR126841A1/es unknown
- 2022-08-22 TW TW111131555A patent/TW202317770A/zh unknown
-
2024
- 2024-02-19 EC ECSENADI202413031A patent/ECSP24013031A/es unknown
- 2024-02-20 CO CONC2024/0001768A patent/CO2024001768A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022328531A1 (en) | 2024-03-14 |
WO2023022631A1 (fr) | 2023-02-23 |
EP4389880A1 (fr) | 2024-06-26 |
CO2024001768A2 (es) | 2024-07-08 |
AR126841A1 (es) | 2023-11-22 |
CN118139974A (zh) | 2024-06-04 |
TW202317770A (zh) | 2023-05-01 |
IL310949A (en) | 2024-04-01 |
CA3229580A1 (fr) | 2023-02-23 |
ECSP24013031A (es) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49599A1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
MA46230A (fr) | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère | |
CA2604532A1 (fr) | Molecules arn a faible activation | |
MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
MA34738B1 (fr) | Neutralisation d'anticorps anti-ccl20 | |
ATE435232T1 (de) | Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden | |
CN116096883A (zh) | Angptl3的碱基编辑和使用其治疗疾病的方法 | |
EA200301169A1 (ru) | АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ CD44v6 | |
US10457631B2 (en) | Biodegradable amino-ester nanomaterials for nucleic acid delivery | |
MA56142A1 (fr) | Protéine modifiée séparée vp1 de capside de aav5 | |
MA62178A1 (fr) | Effet synergique de smn1 et mir-23a dans le traitement de l'amyotrophie spinale | |
MA64631A1 (fr) | Procédé de production de capside modifié de virus adéno-associé | |
Sun et al. | Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help | |
CN1646702A (zh) | 用于治疗性寡核苷酸的蛋白质载体系统 | |
ZA202306901B (en) | Ionizable lipids | |
HUP0303431A2 (hu) | PRRS vírus élő legyengített törzsei | |
CO2022016956A2 (es) | Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd) | |
WO2023031392A3 (fr) | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques comprenant de la phosphatidylsérine | |
US20240247265A1 (en) | Constructs and methods for preparing circular rna | |
CA2470579A1 (fr) | Production efficace de fragments f(ab')2 dans des cellules de mammiferes | |
FR3104976B1 (fr) | Composition à base de rétinol | |
DE60325838D1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine | |
MA64618A1 (fr) | Protéine modifiée séparée vp1 de capside aav9 | |
WO2004101801A3 (fr) | Methode amelioree pour produire des preparations a base de vecteurs amplicon herpes virus non pathogenes, exemptes de virus auxiliaires, virus auxiliaire et cellules utilises selon cette methode, outils genetiques correspondants, et applications de ces vecteurs amplicon non pathogenes | |
CN1837191A (zh) | 一种n-乙酰基半胱氨酸衍生物与应用 |